The inhibitory effect of sulphonylurea derivatives on liver glycogenolysis increased by catecholamines.
D000818:Animals; D002271:Carbutamide / Q000494:pharmacology; D002395:Catecholamines / Q000037:antagonists & inhibitors*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002747:Chlorpropamide / Q000494:pharmacology; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005947:Glucose / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology; D051381:Rats
D002395:Catecholamines; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D011433:Propranolol; D002271:Carbutamide; D005947:Glucose; D007545:Isoproterenol; D002747:Chlorpropamide; D004837:Epinephrine